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INTRODUCTION AND OBJECTIVES: To examine representation in urological subspecialties in relation to surgeon gender and characterize practice patterns among certifying urologists over the last 13 years.
METHODS: Demographic and case log data of certifying and recertifying urologists (2004 to 2015) was obtained from the American Board of Urology (ABU). We investigated gender-specific trends in selfreported practice type (academic or private practice), sub-specialization, and employment as a full-time versus part-time physician, relative to certification year and cycle.
RESULTS: Of a total of 9,140 urologists applying for certification or recertification over the study period, 815 (8.9%) were women, with first time certifiers representing the largest proportion of women surgeon candidates at 65.0% of all women certifying and 16.7% of total first time certifying urologists (p<0.001). 23.6% of women surgeons identified their practice as being academic compared to 13.7% of their male colleagues(p<0.001). Women surgeons identify as sub-specialists in greater numbers (46.4%) than their male counterparts (23.4%) across all certification cycle cohorts and certification years (p<0.001). 25.4% of all women urologists requesting certification identify as subspecialists in female urology and 10.4% in pediatrics compared to 4.8% and 3.1% of their male colleagues respectively (both p<0.001). Female and male surgeons request certification in equal proportion in infertility (1.9% women compared to 1.8% men). Female surgeons however lag behind their male colleagues in oncology (4.5% compared to 7.6%) as well as endourology and stone disease (4.0% women compared to 6.1% men) across all certification years.
CONCLUSIONS: A growing proportion of certifying urologists are women surgeons, who are disproportionately first time certifiers. Women surgeons account for a disproportionate volume of urologists who practice in the academic setting and identify as sub-specialists.
Source of Funding: None

MP86-19 FEMALE UROLOGY RESIDENT REPRESENTATION AT SECTIONAL MEETINGS e DO WE HAVE A GENDER DISPARITY ISSUE?
Tony Lin*, Hershey, PA; Adam Klausner, Richmond, VA; Jay Raman, Hershey, PA INTRODUCTION AND OBJECTIVES: The number of female urology residents in the United States has continued to rise over the past 10 years. The representation of this cohort in an academic meeting setting has not been fully defined. We reviewed abstracts from the Mid-Atlantic American Urological Association (MAAUA) sectional meetings to determine if this increase in female urology residents mirrored an increase in this group 0 s abstract authorship.
METHODS: Full text abstracts from the MAAUA meetings were analyzed from 2008-2014 excluding one joint section meeting. The first author 0 s gender was ascertained from institutional websites, social media, and U.S. News and World Report. If still uncertain, then the gender was classified as 00 unknown 00 and such abstracts were not included in the analysis. The abstracts were categorized as pertaining to general urology, endourology, oncology, reconstruction/trauma, pediatrics, robotic/laparoscopic, female pelvic medicine, and education/ other. RESULTS: A total of 484 abstracts were analyzed. Of these, 393 (81%) were first authored by men, 81 (17%) by women, and 10 (2%) having an unknown gender. The disparity between men and women authorship was significant at all years of evaluation (p < 0.0001) with a declining trend of female first authorship across the study years. (Figure 1 ) Subgroup analysis across urology specialties highlighted significantly greater male first author representation in all topic areas including female pelvic medicine. (Figure 2) CONCLUSIONS: Despite an increasing number of female urology residents, representation at one AUA sectional meeting over the past 7 years remained disproportionately low. Additionally, analysis of trends revealed a slight decrease over the same time period. While this may be a function of smaller sample size, these data underscore the need for closer evaluation of the reasons underlying this trend.
INTRODUCTION AND OBJECTIVES: Prostate-specific antigen (PSA) screening in men of average risk remains controversial. Results from PSA clinical trials are widely cited in patient education materials, but patients' ability to incorporate probability and risk data into their decision-making may depend on their numeracy, or facility with quantitative concepts. This study assessed men's numeracy and its impact on their understanding of the risk reduction benefits of PSA screening.
METHODS: Cross-sectional survey study. Men 40-75 years old attending a general medicine clinic were invited to complete a survey, which included demographics, personal PSA and prostate cancer (CaP) history, and a validated 3-item numeracy test. Numeracy was scored as the number of items correctly answered (range 0-3). Surveys also presented PSA risk reduction data derived from the European Randomized Study of Screening for Prostate Cancer, framed in 1 of 4 ways: absolute or relative risk reduction (ARR or RRR), with or without baseline risk (BR). Respondents were asked to adjust their perceived risk of CaP mortality using the risk data presented. Accuracy of risk reduction was evaluated relative to how risk data were framed.
RESULTS: 200 men completed the survey (60% response rate). Mean age was 60 years, 51% had received a PSA test, and 5% reported a CaP diagnosis. Respondents' demographics were not significantly different among the 4 survey formats. Most men incorrectly answered 1 or more of the 3 numeracy items; half could not convert "1 in 1000" to a percentage, and one-quarter could not calculate "1% of 1000." Overall accuracy of perceived risk adjustment based on PSA data was 20% among all groups. Accuracy varied with how data were framed: when presented with RRR, men were 13% accurate without BR and 31% accurate with BR; when presented with ARR, they were 0% accurate without BR and 35% accurate with BR. Including BR data significantly improved accuracy for both RRR (P¼0.03) and ARR groups (P<0.01). Accuracy was significantly related to numeracy; numeracy scores of 0, 1, 2, and 3 were associated with accuracy rates of 6%, 5%, 9%, and 36%, respectively (P<0.01). Neither PSA testing history nor CaP history was associated with accuracy.
CONCLUSIONS: Patients' numeracy was significantly associated with the accuracy of interpreting quantitative benefits of PSA screening. Although accuracy improved when the presentation of risk reduction data was framed by baseline risk, numeracy in this screening population of men was poor overall. Alternative methods of communicating concepts of risk to patients may facilitate shared decisionmaking. INTRODUCTION AND OBJECTIVES: Elevated glucose uptake and lactate production in the availability of oxygen, a phenomenon called the Warburg effect, is important for cancer cell growth. Phosphorylation of Pyruvate kinase isozyme M2 (PKM2) by ERK promotes its nuclear localization and the Warburg effect. O-class forkhead factor 1 (FOXO1) acts as a tumor suppressor in the nucleus. FOXO1 can be phosphorylated by activated AKT and exported to cytoplasm, thereby losing its tumor suppressor function. Here, we revealed that AKTphosphorylated FOXO1 inhibits IQGAP1-augmented activation of ERK. We also investigated whether AKT-phosphorylated FOXO1 inhibits PKM2 nuclear localization and Warburg effect in prostate cancer.
Source of Funding: None
METHODS: We used co-IP to determine protein interaction, Western-blot to detect the protein level, RT-PCR to detect gene expression level, immunocytochemistry to detect PKM2 cellular localization, immunohistochemistry to analysize FOXO1 and phosphor-ERK level in human prostate cancer using tissue microarray (TMA). Glucose or lactate levels were determined using a glucose assay kit or lactate assay kit. IQBP was a small phosphor-mimicking peptide derived from FOXO1. PC-3-Luc cells were injected into NSG mice to generate xenograft model. RESULTS: We identified the scaffold protein IQGAP1 as a binding partner of FOXO1 (Fig. a) . We demonstrated that activated AKT is important for FOXO1-IQGAP1 interaction (Fig. b and c) , and AKTphosphorylated FOXO1 at serine-319 is critical for FOXO1 binding to IQGAP1 (Fig. d) . Phosphorylated FOXO1 inhibits IQGAP1-augmented phosphorylation of ERK( Fig. e-g) . We also found that there is an inverse correlation between FOXO1 and phosphorylated ERK1/2 in human prostate cancer tissues ( Fig. h and i) . Phosphorylated FOXO1 (cytoplasmic) inhibits PKM2 nuclear localization ( Fig. j) and knockdown of FOXO1 promotes PKM2 nuclear localization (Fig. k) . We further demonstrated that phosphorylated FOXO1 (cytoplasmic) inhibits
